As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an investigational treatment for adults with treatment-resistant depression ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. Supernus Pharmaceuticals beat ...

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland ...

Highlights,Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals, reflecting growing institutional ...

Also Read: ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug There was no treatment difference between SPN-820 and placebo in the change ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on SUPN: Supernus Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...